The anterior uveitis treatment market share is expected to surge to USD 145.89 million from 2021 to 2026, at an accelerating CAGR of 5.09%.
This anterior uveitis treatment market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers anterior uveitis treatment market segmentation by the following:
- Type - Medications and surgery
- Geography - North America, Asia, Europe, and Rest of World (ROW)
What will the Anterior Uveitis Treatment Market Size be During the Forecast Period?
Download the Free Report Sample to Unlock the Anterior Uveitis Treatment Market Size for the Forecast Period and Other Important Statistics
The anterior uveitis treatment market report also offers information on several market vendors, including AbbVie Inc., Alimera Sciences Inc., Allergan Plc, Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Clearside Biomedical, Enzo Biochem Inc., EyePoint Pharmaceuticals Inc., Kiora Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Viatris Inc., Aldeyra Therapeutics Inc., American Academy of Ophthalmology, L V PRASAD EYE INSTITUTE, Melinta Therapeutics LLC, and Prometheus Laboratories Inc. among others.
Anterior Uveitis Treatment Market: Key Drivers, Trends, and Challenges
The increasing healthcare spending worldwide is notably driving the anterior uveitis treatment market growth, although factors such as high cost of healthcare may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the anterior uveitis treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Anterior Uveitis Treatment Market Driver
-
One of the key factors driving the global anterior uveitis treatment market growth is the increasing healthcare spending worldwide.
- According to the World Health Organization (WHO), the global spending on healthcare continually rose between 2000 and 2018 and reached USD 8.3 trillion or 10% of global GDP.
- In 2020, the US spent 19.7% of its GDP on healthcare expenditure.
- Other European nations such as Germany, France, Sweden, and Austria spent 11.43%, 11.26%, 10.90%, and 10.33%, respectively, of their GDP on healthcare expenditure.
- The increasing expenditure in the global healthcare sector and the increase in government aid to healthcare providers will boost the growth of the global anterior uveitis treatment market during the forecast period.
Key Anterior Uveitis Treatment Market Trend
- Another key factor driving the global anterior uveitis treatment market growth is the increasing geriatric population.
- According to the United Nations Department of Economic Affairs (UN DESA), globally, there were 703 million geriatric population aged 65 years and above in 2019. Eastern and South-Eastern Asia were home to the largest number of the world's geriatric population, with 260 million people falling into the age group of 65 years and above.
- In countries such as the US and Canada, approximately 17% of the population was aged above 65 years in 2019, which is expected to increase to 20% and more by 2030.
- According to the OECD, multi-morbidity is far more common in the geriatric population. 58% of adults belonging to the 65 years and above age group reported having two or more chronic diseases, with this figure rising to 70% or higher in countries such as Portugal, Hungary, Poland, and Germany. Such factors are expected to further support the market growth in the coming years.
Key Anterior Uveitis Treatment Market Challenge
- One of the key challenges to the global anterior uveitis treatment market growth is the high cost of healthcare.
- The US has the most expensive healthcare system compared to other nations.
- According to the Organization for Economic Co-operation and Development (OECD), in 2019, the per capita expenditure on healthcare was USD 10,948 in the US. In 2019, the per capita healthcare expenditure was USD 7,138 in Switzerland, USD 6,748 in Norway, and USD 6,731 in Germany.
- In developing countries like India, China, Brazil, Argentina, and others, due to lack of resources and low per capita income, patients are unable to avail of anterior uveitis treatment.
- The absence of proper healthcare infrastructure and less amount government aids received in the form of medical expense reimbursement further acts as a challenge for the patients in these countries. This will negatively affect the growth of the global anterior uveitis treatment market during the forecast period.
This anterior uveitis treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Who are the Major Anterior Uveitis Treatment Market Vendors?
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
- AbbVie Inc.
- Alimera Sciences Inc.
- Allergan Plc
- Bausch Health Companies Inc.
- Cadila Pharmaceuticals Ltd.
- Clearside Biomedical
- Enzo Biochem Inc.
- EyePoint Pharmaceuticals Inc.
- Kiora Pharmaceuticals, Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Santen Pharmaceutical Co. Ltd.
- Viatris Inc.
- Aldeyra Therapeutics Inc.
- American Academy of Ophthalmology
- L V PRASAD EYE INSTITUTE
- Melinta Therapeutics LLC
- Prometheus Laboratories Inc.
This statistical study of the anterior uveitis treatment market encompasses successful business strategies deployed by the key vendors. The anterior uveitis treatment market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
Product Insights and News
- Abbvie Inc. - The company offers HUMIRA to treat certain forms of non-infectious uveitis, a disease that can severely impact vision.
- Allergan Plc - The company offers ILUVIEN for the treatment of non-infectious posterior uveitis.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The anterior uveitis treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Which are the Key Regions for Anterior Uveitis Treatment Market?
For more insights on the market share of various regions Request for a FREE sample now!
32% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for anterior uveitis treatment in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).
The advanced healthcare infrastructure in the region, the strong market presence of the leading vendors, and the high revenue generated by these vendors will facilitate the anterior uveitis treatment market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
In 2020, the COVID-19 pandemic had a negative impact on the regional anterior uveitis treatment market as the prominent vendors in the market faced supply chain disruptions due to a shortage of raw materials, which negatively impacted the sales of anterior uveitis treatment drugs. In H2 2020, due to the availability of vaccines and reduction in COVID-19 cases in the region, the supply chain disruptions faced by the regional vendors eased up, which led to the availability of the various medications for the treatment of anterior uveitis. These factors will contribute to the growth of the regional anterior uveitis treatment market during the forecast period.
What are the Revenue-generating Type Segments in the Anterior Uveitis Treatment Market?
To gain further insights on the market contribution of various segments Request for a FREE sample
The anterior uveitis treatment market share growth by the medications segment will be significant during the forecast period. The wide range of prescription medications available for the treatment of anterior uveitis will contribute to the growth of the market segment during the forecast period. For instance, prominent vendors in the market, such as Novartis AG, offer corticosteroid eye drops for the treatment of anterior uveitis under the brand name Durezol.
This report provides an accurate prediction of the contribution of all the segments to the growth of the anterior uveitis treatment market size and actionable market insights on post COVID-19 impact on each segment.
Parent Market Analysis
Technavio categorizes the global anterior uveitis treatment market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the anterior uveitis treatment market during the forecast period.
Anterior Uveitis Treatment Market Value Chain Analysis
Our report provides extensive information on the value chain analysis for the anterior uveitis treatment market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
Anterior Uveitis Treatment Market Scope
|
Report Coverage
|
Details
|
Page number
|
120
|
Base year
|
2021
|
Forecast period
|
2022-2026
|
Growth momentum & CAGR
|
Accelerate at a CAGR of 5.09%
|
Market growth 2022-2026
|
$ 145.89 million
|
Market structure
|
Fragmented
|
YoY growth (%)
|
3.52
|
Regional analysis
|
North America, Asia, Europe, and Rest of World (ROW)
|
Performing market contribution
|
North America at 32%
|
Key consumer countries
|
US, Canada, Germany, China, and India
|
Competitive landscape
|
Leading companies, Competitive strategies, Consumer engagement scope
|
Key companies profiled
|
AbbVie Inc., Alimera Sciences Inc., Allergan Plc, Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Clearside Biomedical, Enzo Biochem Inc., EyePoint Pharmaceuticals Inc., Kiora Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Viatris Inc., Aldeyra Therapeutics Inc., American Academy of Ophthalmology, L V PRASAD EYE INSTITUTE, Melinta Therapeutics LLC, and Prometheus Laboratories Inc.
|
Market dynamics
|
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
|
Customization purview
|
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
|
Request for a FREE sample
What are the Key Data Covered in this Anterior Uveitis Treatment Market Report?
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will drive anterior uveitis treatment market growth during the next five years
- Precise estimation of the anterior uveitis treatment market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the anterior uveitis treatment industry across North America, Asia, Europe, and Rest of World (ROW)
- A thorough analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of anterior uveitis treatment market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Type
- 5.1 Market segments
- Exhibit 24: Chart on Type - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
- 5.2 Comparison by Type
- Exhibit 26: Chart on Comparison by Type
- Exhibit 27: Data Table on Comparison by Type
- 5.3 Medications - Market size and forecast 2021-2026
- Exhibit 28: Chart on Medications - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Medications - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Medications - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Medications - Year-over-year growth 2021-2026 (%)
- 5.4 Surgery - Market size and forecast 2021-2026
- Exhibit 32: Chart on Surgery - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Surgery - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Surgery - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Surgery - Year-over-year growth 2021-2026 (%)
- 5.5 Market opportunity by Type
- Exhibit 36: Market opportunity by Type ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 38: Chart on Market share by geography 2021-2026 (%)
- Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 40: Chart on Geographic comparison
- Exhibit 41: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Asia - Market size and forecast 2021-2026
- Exhibit 46: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.5 Europe - Market size and forecast 2021-2026
- Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Canada - Market size and forecast 2021-2026
- Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.9 China - Market size and forecast 2021-2026
- Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.10 India - Market size and forecast 2021-2026
- Exhibit 70: Chart on India - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on India - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on India - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on India - Year-over-year growth 2021-2026 (%)
- 7.11 Germany - Market size and forecast 2021-2026
- Exhibit 74: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 78: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.3 Impact of drivers and challenges
- Exhibit 79: Impact of drivers and challenges in 2021 and 2026
9 Vendor Landscape
- 9.2 Vendor landscape
- Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 81: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 82: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 83: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 84: Matrix on vendor position and classification
- 10.3 AbbVie Inc.
- Exhibit 85: AbbVie Inc. - Overview
- Exhibit 86: AbbVie Inc. - Business segments
- Exhibit 87: AbbVie Inc. - Key offerings
- Exhibit 88: AbbVie Inc. - Segment focus
- 10.4 Alimera Sciences Inc.
- Exhibit 89: Alimera Sciences Inc. - Overview
- Exhibit 90: Alimera Sciences Inc. - Product / Service
- Exhibit 91: Alimera Sciences Inc. - Key offerings
- 10.5 Bausch Health Companies Inc.
- Exhibit 92: Bausch Health Companies Inc. - Overview
- Exhibit 93: Bausch Health Companies Inc. - Business segments
- Exhibit 94: Bausch Health Companies Inc. - Key news
- Exhibit 95: Bausch Health Companies Inc. - Key offerings
- Exhibit 96: Bausch Health Companies Inc. - Segment focus
- 10.6 Clearside Biomedical
- Exhibit 97: Clearside Biomedical - Overview
- Exhibit 98: Clearside Biomedical - Key news
- Exhibit 99: Clearside Biomedical - Key offerings
- 10.7 Enzo Biochem Inc.
- Exhibit 100: Enzo Biochem Inc. - Overview
- Exhibit 101: Enzo Biochem Inc. - Key offerings
- 10.8 EyePoint Pharmaceuticals Inc.
- Exhibit 102: EyePoint Pharmaceuticals Inc. - Overview
- Exhibit 103: EyePoint Pharmaceuticals Inc. - Product / Service
- Exhibit 104: EyePoint Pharmaceuticals Inc. - Key offerings
- 10.9 Kiora Pharmaceuticals, Inc.
- Exhibit 105: Kiora Pharmaceuticals, Inc. - Overview
- Exhibit 106: Kiora Pharmaceuticals, Inc. - Product / Service
- Exhibit 107: Kiora Pharmaceuticals, Inc. - Key offerings
- 10.10 Novartis AG
- Exhibit 108: Novartis AG - Overview
- Exhibit 109: Novartis AG - Business segments
- Exhibit 110: Novartis AG - Key offerings
- Exhibit 111: Novartis AG - Segment focus
- 10.11 Pfizer Inc.
- Exhibit 112: Pfizer Inc. - Overview
- Exhibit 113: Pfizer Inc. - Business segments
- Exhibit 114: Pfizer Inc. - Key news
- Exhibit 115: Pfizer Inc. - Key offerings
- Exhibit 116: Pfizer Inc. - Segment focus
- 10.12 Santen Pharmaceutical Co. Ltd.
- Exhibit 117: Santen Pharmaceutical Co. Ltd. - Overview
- Exhibit 118: Santen Pharmaceutical Co. Ltd. - Business segments
- Exhibit 119: Santen Pharmaceutical Co. Ltd. - Key offerings
- Exhibit 120: Santen Pharmaceutical Co. Ltd. - Segment focus
11 Appendix
- 11.2 Inclusions and exclusions checklist
- Exhibit 121: Inclusions checklist
- Exhibit 122: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 123: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 124: Research methodology
- Exhibit 125: Validation techniques employed for market sizing
- Exhibit 126: Information sources
- 11.5 List of abbreviations
- Exhibit 127: List of abbreviations